Life Sciences SPAC Pulls Plans For $200M IPO
Life sciences-focused special-purpose acquisition company HighCape Capital Acquisition Corp. II on Thursday told regulators it was withdrawing plans for a $200 million initial public offering, a move that adds to a...To view the full article, register now.
Already a subscriber? Click here to view full article